Drug intelligence / Profile preview

1,4-phenylenebis(methylene)selenocyanate

Development stage
Preclinical
Lead developer
The Pennsylvania State University
Modality
Small Molecules
Administration
Oral
01

Overview

p-XSC (1,4-phenylenebis(methylene)selenocyanate) is a synthetic organoselenium compound developed as a chemopreventive and therapeutic agent, particularly for prostate cancer. It is designed to provide the beneficial effects of selenium with lower toxicity and higher efficacy than naturally occurring selenium compounds like selenomethionine. Mechanistically, p-XSC inhibits the mammalian target of rapamycin complex 2 (mTORC2) signaling pathway by disrupting the interaction between mTOR and Rictor, which leads to decreased phosphorylation of the downstream target Akt. Additionally, p-XSC has been shown to down-regulate the expression and transcriptional activity of the androgen receptor (AR) in both androgen-responsive and androgen-independent prostate cancer cells. Preclinical studies suggest that p-XSC may be effective against advanced and hormone-refractory prostate disease, either as a monotherapy or in combination with mTORC1 inhibitors like rapamycin.

Other names
1,4-phenylenebis(methylene)selenocyanatepara-xyleneselenocyanate
02

Targets

AR (Adrenergic receptors)Mechanistic target of rapamycin kinase complex 2

Beyond the preview

Go deeper on 1,4-phenylenebis(methylene)selenocyanate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1,4-phenylenebis(methylene)selenocyanate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call